VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q85809986  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241020233040.0
008     241020nneanz||abbn n and d
035 ‎‡a  (WKP)Q85809986‏
024 ‎‡a  0000-0001-5258-7921‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q85809986‏
100 0 ‎‡a  Mariana P C Ribeiro‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Mariana P C Ribeiro‏ ‎‡c  onderzoeker‏ ‎‡9  nl‏
670 ‎‡a  Author's A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer‏
670 ‎‡a  Author's Atypical cyclins: the extended family portrait‏
670 ‎‡a  Author's Comprehensive and quantitative analysis of G1 cyclins. A tool for studying the cell cycle‏
670 ‎‡a  Author's Effects of all-trans-retinoic acid on the permeability transition and bioenergetic functions of rat liver mitochondria in combination with endoxifen.‏
670 ‎‡a  Author's Interplay between estrogen and retinoid signaling in breast cancer--current and future perspectives‏
670 ‎‡a  Author's Ionotropic glutamate receptor antagonists and cancer therapy: time to think out of the box?‏
670 ‎‡a  Author's Live fast, die soon: cell cycle progression and lifespan in yeast cells‏
670 ‎‡a  Author's Mitochondria: the gateway for tamoxifen-induced liver injury.‏
670 ‎‡a  Author's Phosphate: from stardust to eukaryotic cell cycle control.‏
670 ‎‡a  Author's Phosphoregulation of the oncogenic protein regulator of cytokinesis 1‏
670 ‎‡a  Author's Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex‏
670 ‎‡a  Author's Polyphosphate is a key factor for cell survival after DNA damage in eukaryotic cells.‏
670 ‎‡a  Author's Polyphosphate: popping up from oblivion‏
670 ‎‡a  Author's Rethinking tamoxifen in the management of melanoma: New answers for an old question‏
670 ‎‡a  Author's The activation of the G protein-coupled estrogen receptor‏
670 ‎‡a  Author's The activation of the G protein-coupled estrogen receptor (GPER) inhibits the proliferation of mouse melanoma K1735-M2 cells‏
670 ‎‡a  Author's The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen.‏
670 ‎‡a  Author's The antiestrogen endoxifen protects rat liver mitochondria from permeability transition pore opening and oxidative stress at concentrations that do not affect the phosphorylation efficiency.‏
670 ‎‡a  Author's The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration‏
670 ‎‡a  Author's The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells.‏
909 ‎‡a  (orcid) 0000000152587921‏ ‎‡9  1‏
919 ‎‡a  systematicanalysisoforphancyclinsrevealscntd2asanewoncogenicdriverinlungcancer‏ ‎‡A  A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer‏ ‎‡9  1‏
919 ‎‡a  comprehensiveandquantitativeanalysisofg1cyclinsatoolforstudyingthecellcycle‏ ‎‡A  Comprehensive and quantitative analysis of G1 cyclins. A tool for studying the cell cycle‏ ‎‡9  1‏
919 ‎‡a  effectsofalltransretinoicacidonthepermeabilitytransitionandbioenergeticfunctionsofratlivermitochondriaincombinationwithendoxifen‏ ‎‡A  Effects of all-trans-retinoic acid on the permeability transition and bioenergetic functions of rat liver mitochondria in combination with endoxifen.‏ ‎‡9  1‏
919 ‎‡a  interplaybetweenestrogenandretinoidsignalinginbreastcancercurrentandfutureperspectives‏ ‎‡A  Interplay between estrogen and retinoid signaling in breast cancer--current and future perspectives‏ ‎‡9  1‏
919 ‎‡a  ionotropicglutamatereceptorantagonistsandcancertherapytimetothinkoutofthebox‏ ‎‡A  Ionotropic glutamate receptor antagonists and cancer therapy: time to think out of the box?‏ ‎‡9  1‏
919 ‎‡a  livefastdiesooncellcycleprogressionandlifespaninyeastcells‏ ‎‡A  Live fast, die soon: cell cycle progression and lifespan in yeast cells‏ ‎‡9  1‏
919 ‎‡a  mitochondriathegatewayfortamoxifeninducedliverinjury‏ ‎‡A  Mitochondria: the gateway for tamoxifen-induced liver injury.‏ ‎‡9  1‏
919 ‎‡a  phosphatefromstardusttoeukaryoticcellcyclecontrol‏ ‎‡A  Phosphate: from stardust to eukaryotic cell cycle control.‏ ‎‡9  1‏
919 ‎‡a  phosphoregulationoftheoncogenicproteinregulatorofcytokinesis1‏ ‎‡A  Phosphoregulation of the oncogenic protein regulator of cytokinesis 1‏ ‎‡9  1‏
919 ‎‡a  phosphoregulationoftheoncogenicproteinregulatorofcytokinesis1prc1bytheatypicalcdk16ccnycomplex‏ ‎‡A  Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex‏ ‎‡9  1‏
919 ‎‡a  polyphosphatepoppingupfromoblivion‏ ‎‡A  Polyphosphate: popping up from oblivion‏ ‎‡9  1‏
919 ‎‡a  rethinkingtamoxifeninthemanagementofmelanomanewanswersforanoldquestion‏ ‎‡A  Rethinking tamoxifen in the management of melanoma: New answers for an old question‏ ‎‡9  1‏
919 ‎‡a  activationofthegproteincoupledestrogenreceptor‏ ‎‡A  The activation of the G protein-coupled estrogen receptor‏ ‎‡9  1‏
919 ‎‡a  activationofthegproteincoupledestrogenreceptorgperinhibitstheproliferationofmousemelanomak1735m2cells‏ ‎‡A  The activation of the G protein-coupled estrogen receptor (GPER) inhibits the proliferation of mouse melanoma K1735-M2 cells‏ ‎‡9  1‏
919 ‎‡a  antiestrogen4hydroxytamoxifenprotectsagainstisotretinoininducedpermeabilitytransitionandbioenergeticdysfunctionoflivermitochondriacomparisonwithtamoxifen‏ ‎‡A  The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen.‏ ‎‡9  1‏
919 ‎‡a  antiestrogenendoxifenprotectsratlivermitochondriafrompermeabilitytransitionporeopeningandoxidativestressatconcentrationsthatdonotaffectthephosphorylationefficiency‏ ‎‡A  The antiestrogen endoxifen protects rat liver mitochondria from permeability transition pore opening and oxidative stress at concentrations that do not affect the phosphorylation efficiency.‏ ‎‡9  1‏
919 ‎‡a  atypicalcyclincntd2promotescoloncancercellproliferationandmigration‏ ‎‡A  The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration‏ ‎‡9  1‏
919 ‎‡a  combinationofglutamatereceptorantagonistmk801withtamoxifenanditsactivemetabolitespotentiatestheirantiproliferativeactivityinmousemelanomak1735m2cells‏ ‎‡A  The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells.‏ ‎‡9  1‏
919 ‎‡a  atypicalcyclinstheextendedfamilyportrait‏ ‎‡A  Atypical cyclins: the extended family portrait‏ ‎‡9  1‏
919 ‎‡a  polyphosphateisakeyfactorforcellsurvivalafterdnadamageineukaryoticcells‏ ‎‡A  Polyphosphate is a key factor for cell survival after DNA damage in eukaryotic cells.‏ ‎‡9  1‏
996 ‎‡2  SUDOC|170319067
996 ‎‡2  LC|n 2012213335
996 ‎‡2  BLBNB|000290987
996 ‎‡2  BLBNB|001579028
996 ‎‡2  PTBNP|1290927
996 ‎‡2  PLWABN|9813293491905606
996 ‎‡2  PTBNP|67293
996 ‎‡2  ISNI|0000000505497359
996 ‎‡2  LC|n 79010096
996 ‎‡2  ISNI|0000000063301047
996 ‎‡2  ISNI|0000000067550542
996 ‎‡2  DNB|1046539582
996 ‎‡2  BLBNB|000484132
996 ‎‡2  ISNI|0000000120507341
996 ‎‡2  PTBNP|89804
996 ‎‡2  PTBNP|149618
996 ‎‡2  BLBNB|000311398
996 ‎‡2  PTBNP|1406802
996 ‎‡2  ISNI|0000000428207521
996 ‎‡2  ISNI|0000000116124735
996 ‎‡2  PTBNP|1674875
996 ‎‡2  ISNI|0000000053770392
996 ‎‡2  DNB|1056708093
996 ‎‡2  PTBNP|1484997
996 ‎‡2  PTBNP|718073
996 ‎‡2  PTBNP|38457
996 ‎‡2  DNB|1157214304
996 ‎‡2  PTBNP|255652
996 ‎‡2  PTBNP|997289
996 ‎‡2  LC|n 84134380
996 ‎‡2  ISNI|0000000068800531
996 ‎‡2  NTA|158680332
996 ‎‡2  NTA|23635891X
996 ‎‡2  ISNI|0000000428320866
996 ‎‡2  PTBNP|228058
996 ‎‡2  ISNI|0000000424600713
996 ‎‡2  ISNI|0000000033432062
996 ‎‡2  BLBNB|001442092
996 ‎‡2  BNF|16745872
996 ‎‡2  PTBNP|1915332
996 ‎‡2  BLBNB|000266524
996 ‎‡2  LC|no2017158721
996 ‎‡2  BLBNB|000182348
996 ‎‡2  ISNI|0000000046078971
996 ‎‡2  ISNI|000000035903251X
996 ‎‡2  ISNI|0000000068306744
996 ‎‡2  LC|no2005000355
996 ‎‡2  PTBNP|1557893
996 ‎‡2  PTBNP|1318766
996 ‎‡2  LC|no2006112870
996 ‎‡2  ISNI|0000000114101257
996 ‎‡2  PTBNP|1241204
996 ‎‡2  ISNI|000000005940297X
996 ‎‡2  BLBNB|000581542
996 ‎‡2  SUDOC|033192529
996 ‎‡2  PTBNP|1742289
996 ‎‡2  ISNI|0000000070230494
996 ‎‡2  BIBSYS|90561709
996 ‎‡2  PTBNP|1401342
996 ‎‡2  ISNI|0000000070517057
996 ‎‡2  RERO|A003510538
996 ‎‡2  PTBNP|212663
996 ‎‡2  PTBNP|1358623
996 ‎‡2  BLBNB|000458530
996 ‎‡2  DNB|1189687453
996 ‎‡2  PTBNP|1189983
996 ‎‡2  BLBNB|000305643
996 ‎‡2  BLBNB|000431403
996 ‎‡2  NUKAT|n 2022068522
996 ‎‡2  ISNI|0000000036193108
996 ‎‡2  BLBNB|000487999
996 ‎‡2  DNB|1056639490
996 ‎‡2  BLBNB|000583696
996 ‎‡2  PTBNP|1767334
996 ‎‡2  PTBNP|1616736
996 ‎‡2  ISNI|0000000070228853
996 ‎‡2  DNB|1053075103
996 ‎‡2  PLWABN|9813281037005606
996 ‎‡2  ISNI|0000000069798787
996 ‎‡2  LIH|LNB:C_h_47;=BM
996 ‎‡2  PTBNP|1380245
996 ‎‡2  BLBNB|000322825
996 ‎‡2  BLBNB|000332705
996 ‎‡2  ISNI|0000000069830126
996 ‎‡2  BLBNB|000332707
996 ‎‡2  BLBNB|000332701
996 ‎‡2  BLBNB|000332700
996 ‎‡2  BLBNB|000332703
996 ‎‡2  LC|nb2004303060
996 ‎‡2  SUDOC|138471665
996 ‎‡2  BLBNB|000332709
996 ‎‡2  BLBNB|000386880
996 ‎‡2  ISNI|0000000068119340
996 ‎‡2  ISNI|0000000072774145
996 ‎‡2  J9U|987007261051305171
996 ‎‡2  BLBNB|000350630
996 ‎‡2  BLBNB|000403225
996 ‎‡2  BLBNB|000435708
996 ‎‡2  BLBNB|000480540
996 ‎‡2  DNB|105330143X
996 ‎‡2  PTBNP|193738
996 ‎‡2  BLBNB|000477528
996 ‎‡2  BNF|17985625
996 ‎‡2  ISNI|0000000069786866
996 ‎‡2  PTBNP|798494
996 ‎‡2  J9U|987007266908505171
996 ‎‡2  ISNI|0000000070394800
996 ‎‡2  BLBNB|001415849
996 ‎‡2  BLBNB|000375882
996 ‎‡2  BLBNB|000352631
996 ‎‡2  DNB|1057442321
996 ‎‡2  ISNI|0000000041431764
996 ‎‡2  LC|no2002103728
996 ‎‡2  ISNI|0000000067669308
996 ‎‡2  ISNI|0000000043865531
996 ‎‡2  PTBNP|1492979
996 ‎‡2  ISNI|0000000070131859
996 ‎‡2  ISNI|0000000030314976
996 ‎‡2  BLBNB|000562118
996 ‎‡2  ISNI|0000000476753738
996 ‎‡2  ISNI|0000000014285044
996 ‎‡2  DNB|1056187913
996 ‎‡2  SUDOC|145478246
996 ‎‡2  PTBNP|218866
996 ‎‡2  PTBNP|43578
996 ‎‡2  ISNI|0000000068209012
996 ‎‡2  PTBNP|1320849
996 ‎‡2  DNB|1167532562
996 ‎‡2  PTBNP|1418341
996 ‎‡2  DNB|1047962152
996 ‎‡2  BLBNB|000424600
996 ‎‡2  PTBNP|40020
996 ‎‡2  LC|no2013023157
996 ‎‡2  ISNI|0000000070803205
996 ‎‡2  ISNI|0000000067343754
996 ‎‡2  NUKAT|n 2019223771
996 ‎‡2  PTBNP|177351
996 ‎‡2  PTBNP|1382281
996 ‎‡2  PTBNP|1742531
996 ‎‡2  DNB|1074946162
996 ‎‡2  PTBNP|57983
996 ‎‡2  PTBNP|35433
996 ‎‡2  ISNI|0000000067680478
996 ‎‡2  NUKAT|n 2017078992
996 ‎‡2  ISNI|0000000044186506
996 ‎‡2  LC|n 82055755
996 ‎‡2  ISNI|0000000367623651
996 ‎‡2  DNB|1053819838
996 ‎‡2  NSK|000320255
996 ‎‡2  ISNI|0000000070126419
996 ‎‡2  BLBNB|000990080
996 ‎‡2  LC|n 91077647
996 ‎‡2  ISNI|0000000382949668
996 ‎‡2  PTBNP|9962
996 ‎‡2  BLBNB|000569010
996 ‎‡2  BNF|15884168
996 ‎‡2  ISNI|0000000070319093
996 ‎‡2  ISNI|0000000066492811
996 ‎‡2  LC|no2006109523
996 ‎‡2  ISNI|0000000428233228
996 ‎‡2  PTBNP|1449345
996 ‎‡2  ISNI|0000000070321644
996 ‎‡2  PTBNP|213013
996 ‎‡2  BLBNB|000234062
996 ‎‡2  PTBNP|1593036
996 ‎‡2  NTA|099982129
996 ‎‡2  PTBNP|96510
996 ‎‡2  JPG|500067122
996 ‎‡2  PTBNP|1591319
996 ‎‡2  LC|no2002063321
996 ‎‡2  ISNI|0000000069424742
996 ‎‡2  NUKAT|n 2010075961
996 ‎‡2  BLBNB|000276519
996 ‎‡2  PTBNP|120511
996 ‎‡2  ISNI|0000000495739288
996 ‎‡2  PTBNP|1292360
996 ‎‡2  DNB|1057115002
996 ‎‡2  ISNI|0000000069998105
996 ‎‡2  BLBNB|000292701
996 ‎‡2  DNB|1333383355
996 ‎‡2  LC|no 99084454
996 ‎‡2  BLBNB|001520873
996 ‎‡2  ISNI|0000000070818167
996 ‎‡2  RERO|A017164221
996 ‎‡2  LC|no2011164335
996 ‎‡2  ISNI|0000000099484770
996 ‎‡2  PTBNP|921419
996 ‎‡2  SUDOC|087225581
996 ‎‡2  BLBNB|000219703
996 ‎‡2  DNB|1044330163
996 ‎‡2  PTBNP|1423134
996 ‎‡2  RERO|A003368809
996 ‎‡2  BLBNB|000553716
996 ‎‡2  SUDOC|144231425
996 ‎‡2  SUDOC|163697213
996 ‎‡2  PTBNP|1229591
996 ‎‡2  LC|n 97092629
996 ‎‡2  LC|nr2001015104
996 ‎‡2  ISNI|0000000069890583
996 ‎‡2  PTBNP|1019698
996 ‎‡2  ISNI|0000000035448156
996 ‎‡2  BLBNB|000531523
996 ‎‡2  LC|n 2020042460
996 ‎‡2  DNB|1043624473
996 ‎‡2  ISNI|0000000029560133
996 ‎‡2  PTBNP|999607
996 ‎‡2  BLBNB|000552561
996 ‎‡2  SUDOC|068896018
996 ‎‡2  PTBNP|1182994
996 ‎‡2  ISNI|0000000030471891
996 ‎‡2  BLBNB|000489273
996 ‎‡2  LC|nb2016011668
996 ‎‡2  BLBNB|000440647
996 ‎‡2  PTBNP|107321
996 ‎‡2  BNF|12137064
996 ‎‡2  ISNI|0000000023736919
996 ‎‡2  PTBNP|107324
996 ‎‡2  LC|n 86077751
996 ‎‡2  BLBNB|000990883
996 ‎‡2  PTBNP|107329
996 ‎‡2  LC|n 2023255449
996 ‎‡2  PTBNP|1742132
996 ‎‡2  ISNI|0000000070230291
996 ‎‡2  SUDOC|156413582
996 ‎‡2  PTBNP|1021320
996 ‎‡2  LC|n 95922577
996 ‎‡2  DNB|1212688651
996 ‎‡2  ISNI|000000004363248X
996 ‎‡2  LC|no2002016377
996 ‎‡2  PTBNP|1700683
996 ‎‡2  SUDOC|159714400
996 ‎‡2  DNB|1060659751
996 ‎‡2  ISNI|0000000116747844
996 ‎‡2  LC|n 94033775
996 ‎‡2  J9U|987007271811305171
996 ‎‡2  BNF|13478965
996 ‎‡2  BLBNB|000587696
996 ‎‡2  PTBNP|967726
996 ‎‡2  LC|n 2022252093
996 ‎‡2  NUKAT|n 2008127261
996 ‎‡2  PTBNP|1018405
996 ‎‡2  CAOONL|ncf11741624
996 ‎‡2  DNB|1179978749
996 ‎‡2  RERO|A023090326
996 ‎‡2  LC|n 88072145
996 ‎‡2  PTBNP|193169
996 ‎‡2  LIH|LNB:C_u_DQ;=B_j_
996 ‎‡2  ISNI|0000000081007052
996 ‎‡2  RERO|A005923523
996 ‎‡2  ISNI|0000000068718394
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏